Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234399 | 1.00 | OPRK1 (0.44) | OPRK1POLBTACR1CNR1MLYCD | |
| SCHEMBL237867 | 1.00 | OPRK1 (0.44) | OPRK1POLBTACR1CNR1MLYCD | |
| SCHEMBL254257 | 0.84 | POLB (0.41) | OPRK1POLBMLYCDFDFT1MTNR1A | |
| SCHEMBL610261 | 0.83 | ALOX5 (0.41) | CNR1MTNR1AMTNR1BEPHX2 | |
| SCHEMBL236761 | 0.82 | EPHX1 (0.41) | OPRK1POLBFDFT1MTNR1AMTNR1B | |
| SCHEMBL2754678 | 0.81 | EPHX1 (0.43) | OPRK1POLBFDFT1MTNR1AMTNR1B | |
| SCHEMBL235291 | 0.81 | EPHX1 (0.43) | OPRK1POLBFDFT1MTNR1AMTNR1B | |
| SCHEMBL235292 | 0.81 | EPHX1 (0.43) | OPRK1POLBFDFT1MTNR1AMTNR1B | |
| SCHEMBL613696 | 0.81 | MTNR1A (0.42) | POLBMTNR1AMTNR1BEPHX2 | |
| SCHEMBL237863 | 0.80 | POLB (0.43) | POLBMLYCDFDFT1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-11-19 | — | — | US | disclosed |
| US-9115056-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150045444-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-02-12 | — | — | US | disclosed |
| US-8895782-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140213617-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8766007-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8492589-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8389771-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130030026-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8299307-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | OPRK1 2366/4885POLB 2236/4885TACR1 4389/4885 |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | PDE6D, STARD3, PDE6C | OPRK1 2366/4885POLB 2236/4885TACR1 4389/4885 |
| US-20130030026-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | OPRK1 2366/4885POLB 2236/4885TACR1 4389/4885 |
| US-20150045444-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | OPRK1 2366/4885POLB 2236/4885TACR1 4389/4885 |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, STARD3, PDE6C | OPRK1 2366/4885POLB 2236/4885TACR1 4389/4885 |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | OPRK1 2366/4885POLB 2236/4885TACR1 4389/4885 |
| US-20140213617-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | OPRK1 2366/4885POLB 2236/4885TACR1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.